Cargando…
Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing
BACKGROUND: Higher mortality of COVID-19 patients with lung disease is a formidable challenge for the health care system. Genetic association between COVID-19 and various lung disorders must be understood to comprehend the molecular basis of comorbidity and accelerate drug development. METHODS: Lung...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447809/ https://www.ncbi.nlm.nih.gov/pubmed/34535131 http://dx.doi.org/10.1186/s12920-021-01079-7 |
_version_ | 1784569096996651008 |
---|---|
author | Das, Asim Bikas |
author_facet | Das, Asim Bikas |
author_sort | Das, Asim Bikas |
collection | PubMed |
description | BACKGROUND: Higher mortality of COVID-19 patients with lung disease is a formidable challenge for the health care system. Genetic association between COVID-19 and various lung disorders must be understood to comprehend the molecular basis of comorbidity and accelerate drug development. METHODS: Lungs tissue-specific neighborhood network of human targets of SARS-CoV-2 was constructed. This network was integrated with lung diseases to build a disease–gene and disease-disease association network. Network-based toolset was used to identify the overlapping disease modules and drug targets. The functional protein modules were identified using community detection algorithms and biological processes, and pathway enrichment analysis. RESULTS: In total, 141 lung diseases were linked to a neighborhood network of SARS-CoV-2 targets, and 59 lung diseases were found to be topologically overlapped with the COVID-19 module. Topological overlap with various lung disorders allows repurposing of drugs used for these disorders to hit the closely associated COVID-19 module. Further analysis showed that functional protein–protein interaction modules in the lungs, substantially hijacked by SARS-CoV-2, are connected to several lung disorders. FDA-approved targets in the hijacked protein modules were identified and that can be hit by exiting drugs to rescue these modules from virus possession. CONCLUSION: Lung diseases are clustered with COVID-19 in the same network vicinity, indicating the potential threat for patients with respiratory diseases after SARS-CoV-2 infection. Pathobiological similarities between lung diseases and COVID-19 and clinical evidence suggest that shared molecular features are the probable reason for comorbidity. Network-based drug repurposing approaches can be applied to improve the clinical conditions of COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-021-01079-7. |
format | Online Article Text |
id | pubmed-8447809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84478092021-09-17 Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing Das, Asim Bikas BMC Med Genomics Research Article BACKGROUND: Higher mortality of COVID-19 patients with lung disease is a formidable challenge for the health care system. Genetic association between COVID-19 and various lung disorders must be understood to comprehend the molecular basis of comorbidity and accelerate drug development. METHODS: Lungs tissue-specific neighborhood network of human targets of SARS-CoV-2 was constructed. This network was integrated with lung diseases to build a disease–gene and disease-disease association network. Network-based toolset was used to identify the overlapping disease modules and drug targets. The functional protein modules were identified using community detection algorithms and biological processes, and pathway enrichment analysis. RESULTS: In total, 141 lung diseases were linked to a neighborhood network of SARS-CoV-2 targets, and 59 lung diseases were found to be topologically overlapped with the COVID-19 module. Topological overlap with various lung disorders allows repurposing of drugs used for these disorders to hit the closely associated COVID-19 module. Further analysis showed that functional protein–protein interaction modules in the lungs, substantially hijacked by SARS-CoV-2, are connected to several lung disorders. FDA-approved targets in the hijacked protein modules were identified and that can be hit by exiting drugs to rescue these modules from virus possession. CONCLUSION: Lung diseases are clustered with COVID-19 in the same network vicinity, indicating the potential threat for patients with respiratory diseases after SARS-CoV-2 infection. Pathobiological similarities between lung diseases and COVID-19 and clinical evidence suggest that shared molecular features are the probable reason for comorbidity. Network-based drug repurposing approaches can be applied to improve the clinical conditions of COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-021-01079-7. BioMed Central 2021-09-17 /pmc/articles/PMC8447809/ /pubmed/34535131 http://dx.doi.org/10.1186/s12920-021-01079-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Das, Asim Bikas Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing |
title | Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing |
title_full | Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing |
title_fullStr | Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing |
title_full_unstemmed | Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing |
title_short | Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing |
title_sort | lung disease network reveals impact of comorbidity on sars-cov-2 infection and opportunities of drug repurposing |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447809/ https://www.ncbi.nlm.nih.gov/pubmed/34535131 http://dx.doi.org/10.1186/s12920-021-01079-7 |
work_keys_str_mv | AT dasasimbikas lungdiseasenetworkrevealsimpactofcomorbidityonsarscov2infectionandopportunitiesofdrugrepurposing |